uniQure Faces Setback in FDA Approval for AMT-130
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Should l Buy QURE?
Source: seekingalpha
- FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
- Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
- Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
- Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.630
Low
33.00
Averages
49.88
High
70.00
Current: 15.630
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Reports 2025 Financial Results and Clinical Progress
- AMT-130 Progress: In September 2025, uniQure reported that AMT-130 clinical trial data showed a significant 75% slowing of disease progression in patients receiving high-dose treatment, offering hope for a potential first disease-modifying therapy for Huntington's disease patients.
- FDA Meeting Outcome: Following a Type A meeting with the FDA, the agency indicated that existing data are insufficient to support a marketing application for AMT-130 and recommended a prospective randomized controlled study; uniQure plans to request a Type B meeting in Q2 2026 to discuss further development.
- Improved Financial Position: As of December 31, 2025, uniQure reported cash and cash equivalents of $622.5 million, expected to fund operations into the second half of 2029, demonstrating strong financial management.
- Clinical Trial Updates: In 2026, uniQure will release updated clinical data for AMT-260 and AMT-191, with the former showing a 92% reduction in seizure frequency for refractory temporal lobe epilepsy and the latter demonstrating significant increases in α-Gal A enzyme activity in Fabry disease patients, further solidifying its leadership in gene therapy.
See More
Mixed Close for US Stocks Amid Iran War Impact
- Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
- Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
- Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
- Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.
See More
uniQure Faces Setback in FDA Approval for AMT-130
- FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
- Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
- Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
- Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.
See More
uniQure Q4 2025 Earnings Call Insights
- Gene Therapy Progress: uniQure's Q4 2025 earnings call highlighted groundbreaking three-year data for AMT-130, showing a 75% slowing of disease progression in Huntington's disease; however, the FDA indicated that the data may not support a BLA submission, creating regulatory uncertainty.
- Financial Performance: Revenue for 2025 was $16.1 million, down from $27.1 million in 2024, primarily due to decreased collaboration and contract manufacturing revenues, indicating challenges in diversifying income streams.
- Increased R&D Expenses: Research and development expenses reached $140.7 million, a $19.4 million increase year-over-year, mainly for AMT-130 BLA submission preparations, reflecting the company's significant investment and associated risks in advancing critical projects.
- Future Outlook: Management plans to request a Type B meeting in Q2 2026 to discuss Phase III design options; despite regulatory challenges, uniQure remains committed to advancing its gene therapies and clinical development efforts.
See More
uniQure Faces Securities Fraud Lawsuit After FDA Setback
- Stock Price Plunge: uniQure N.V. shares fell over 35% on March 2, 2026, following the FDA's negative feedback on its AMT-130 gene therapy clinical data, which not only undermines investor confidence but may also affect the company's future financing capabilities.
- Lawsuit Initiation: A securities class action has been filed against uniQure and certain executives for misleading investors about the strength of clinical results and regulatory prospects between September 24 and October 31, 2025, highlighting significant deficiencies in the company's information disclosure practices.
- Historical Stock Volatility: On November 3, 2025, uniQure's stock price had previously dropped by 66% due to FDA feedback regarding inadequate clinical data, indicating ongoing challenges in regulatory compliance that could impact its market position.
- Investor Action Recommendation: Investors are advised to contact Block & Leviton by April 13, 2026, to seek appointment as lead plaintiff; those who take no action will be considered absent class members and may lose their opportunity for recovery.
See More
Iran War Drives Market Volatility and Sector Performance
- Market Reaction: Stocks initially retreated following the US and Israel's joint military actions against Iran, but rebounded after the February ISM manufacturing index exceeded expectations, indicating investor focus on economic data.
- Surge in Energy Prices: The halt of tanker traffic through the Strait of Hormuz due to Iran's attacks on three oil tankers led to WTI crude oil prices soaring over 65% to an 8.25-month high, potentially exacerbating global inflationary pressures.
- Defense Stocks Rise: The ongoing conflict in Iran has bolstered earnings prospects for defense companies, with Aerovironment's stock rising over 12%, while Northrop Grumman and RTX Corp also saw increases of over 4%, reflecting market optimism about defense spending.
- Economic Data Focus: Investors are keenly awaiting upcoming economic data releases, including ADP employment changes and the ISM services index, which are expected to influence future monetary policy directions amid rising inflation concerns.
See More
uniQure Reports 2025 Financial Results and Clinical Progress
- AMT-130 Progress: In September 2025, uniQure reported that AMT-130 clinical trial data showed a significant 75% slowing of disease progression in patients receiving high-dose treatment, offering hope for a potential first disease-modifying therapy for Huntington's disease patients.
- FDA Meeting Outcome: Following a Type A meeting with the FDA, the agency indicated that existing data are insufficient to support a marketing application for AMT-130 and recommended a prospective randomized controlled study; uniQure plans to request a Type B meeting in Q2 2026 to discuss further development.
- Improved Financial Position: As of December 31, 2025, uniQure reported cash and cash equivalents of $622.5 million, expected to fund operations into the second half of 2029, demonstrating strong financial management.
- Clinical Trial Updates: In 2026, uniQure will release updated clinical data for AMT-260 and AMT-191, with the former showing a 92% reduction in seizure frequency for refractory temporal lobe epilepsy and the latter demonstrating significant increases in α-Gal A enzyme activity in Fabry disease patients, further solidifying its leadership in gene therapy.
See More
Mixed Close for US Stocks Amid Iran War Impact
- Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
- Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
- Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
- Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.
See More
uniQure Faces Setback in FDA Approval for AMT-130
- FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
- Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
- Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
- Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.
See More
uniQure Q4 2025 Earnings Call Insights
- Gene Therapy Progress: uniQure's Q4 2025 earnings call highlighted groundbreaking three-year data for AMT-130, showing a 75% slowing of disease progression in Huntington's disease; however, the FDA indicated that the data may not support a BLA submission, creating regulatory uncertainty.
- Financial Performance: Revenue for 2025 was $16.1 million, down from $27.1 million in 2024, primarily due to decreased collaboration and contract manufacturing revenues, indicating challenges in diversifying income streams.
- Increased R&D Expenses: Research and development expenses reached $140.7 million, a $19.4 million increase year-over-year, mainly for AMT-130 BLA submission preparations, reflecting the company's significant investment and associated risks in advancing critical projects.
- Future Outlook: Management plans to request a Type B meeting in Q2 2026 to discuss Phase III design options; despite regulatory challenges, uniQure remains committed to advancing its gene therapies and clinical development efforts.
See More
uniQure Faces Securities Fraud Lawsuit After FDA Setback
- Stock Price Plunge: uniQure N.V. shares fell over 35% on March 2, 2026, following the FDA's negative feedback on its AMT-130 gene therapy clinical data, which not only undermines investor confidence but may also affect the company's future financing capabilities.
- Lawsuit Initiation: A securities class action has been filed against uniQure and certain executives for misleading investors about the strength of clinical results and regulatory prospects between September 24 and October 31, 2025, highlighting significant deficiencies in the company's information disclosure practices.
- Historical Stock Volatility: On November 3, 2025, uniQure's stock price had previously dropped by 66% due to FDA feedback regarding inadequate clinical data, indicating ongoing challenges in regulatory compliance that could impact its market position.
- Investor Action Recommendation: Investors are advised to contact Block & Leviton by April 13, 2026, to seek appointment as lead plaintiff; those who take no action will be considered absent class members and may lose their opportunity for recovery.
See More
Iran War Drives Market Volatility and Sector Performance
- Market Reaction: Stocks initially retreated following the US and Israel's joint military actions against Iran, but rebounded after the February ISM manufacturing index exceeded expectations, indicating investor focus on economic data.
- Surge in Energy Prices: The halt of tanker traffic through the Strait of Hormuz due to Iran's attacks on three oil tankers led to WTI crude oil prices soaring over 65% to an 8.25-month high, potentially exacerbating global inflationary pressures.
- Defense Stocks Rise: The ongoing conflict in Iran has bolstered earnings prospects for defense companies, with Aerovironment's stock rising over 12%, while Northrop Grumman and RTX Corp also saw increases of over 4%, reflecting market optimism about defense spending.
- Economic Data Focus: Investors are keenly awaiting upcoming economic data releases, including ADP employment changes and the ISM services index, which are expected to influence future monetary policy directions amid rising inflation concerns.
See More
